Early symptoms and sensations as predictors of lung cancer: a machine learning multivariate model.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 11 2019
Historique:
received: 12 05 2019
accepted: 23 10 2019
entrez: 13 11 2019
pubmed: 13 11 2019
medline: 5 11 2020
Statut: epublish

Résumé

The aim of this study was to identify a combination of early predictive symptoms/sensations attributable to primary lung cancer (LC). An interactive e-questionnaire comprised of pre-diagnostic descriptors of first symptoms/sensations was administered to patients referred for suspected LC. Respondents were included in the present analysis only if they later received a primary LC diagnosis or had no cancer; and inclusion of each descriptor required ≥4 observations. Fully-completed data from 506/670 individuals later diagnosed with primary LC (n = 311) or no cancer (n = 195) were modelled with orthogonal projections to latent structures (OPLS). After analysing 145/285 descriptors, meeting inclusion criteria, through randomised seven-fold cross-validation (six-fold training set: n = 433; test set: n = 73), 63 provided best LC prediction. The most-significant LC-positive descriptors included a cough that varied over the day, back pain/aches/discomfort, early satiety, appetite loss, and having less strength. Upon combining the descriptors with the background variables current smoking, a cold/flu or pneumonia within the past two years, female sex, older age, a history of COPD (positive LC-association); antibiotics within the past two years, and a history of pneumonia (negative LC-association); the resulting 70-variable model had accurate cross-validated test set performance: area under the ROC curve = 0.767 (descriptors only: 0.736/background predictors only: 0.652), sensitivity = 84.8% (73.9/76.1%, respectively), specificity = 55.6% (66.7/51.9%, respectively). In conclusion, accurate prediction of LC was found through 63 early symptoms/sensations and seven background factors. Further research and precision in this model may lead to a tool for referral and LC diagnostic decision-making.

Identifiants

pubmed: 31712735
doi: 10.1038/s41598-019-52915-x
pii: 10.1038/s41598-019-52915-x
pmc: PMC6848139
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16504

Références

Thorax. 2005 Dec;60(12):1059-65
pubmed: 16227326
Lung Cancer. 2002 Apr;36(1):9-14
pubmed: 11891027
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Natl Cancer Inst. 2007 May 2;99(9):715-26
pubmed: 17470739
PLoS One. 2018 Nov 21;13(11):e0207686
pubmed: 30462699
Thorax. 2005 Apr;60(4):314-9
pubmed: 15790987
Soc Sci Med. 2006 Mar;62(6):1381-91
pubmed: 16168544
N Engl J Med. 2009 Dec 3;361(23):2221-9
pubmed: 19955524
BMJ Open. 2012 Nov 19;2(6):
pubmed: 23166137
BMJ. 2007 May 19;334(7602):1040
pubmed: 17493982
Cancer Imaging. 2011 Oct 03;11 Spec No A:S79-84
pubmed: 22185865
Br J Gen Pract. 2011 Nov;61(592):e715-23
pubmed: 22054335
Br J Gen Pract. 2013 Jan;63(606):e37-46
pubmed: 23336459
Br J Cancer. 2008 Jan 29;98(2):270-6
pubmed: 18087271
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Thorax. 2013 May;68(5):451-9
pubmed: 23321602
Chest. 2013 May;143(5 Suppl):e1S-e29S
pubmed: 23649439
Mol Biosyst. 2015 Jan;11(1):13-9
pubmed: 25382277
Eur J Cancer Care (Engl). 2017 May;26(3):
pubmed: 28497588
JAMA Oncol. 2018 Oct 1;4(10):e182078
pubmed: 30003238
Lancet Oncol. 2017 Dec;18(12):e754-e766
pubmed: 29208441
Prev Med. 2002 Apr;34(4):436-44
pubmed: 11914050
Br J Cancer. 2015 Mar 31;112 Suppl 1:S6-13
pubmed: 25734397
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692

Auteurs

Adrian Levitsky (A)

Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, SE-171 77, Solna, Sweden.
Cancer Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, SE-171 65, Solna, Sweden.

Maria Pernemalm (M)

Cancer Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, SE-171 65, Solna, Sweden.

Britt-Marie Bernhardson (BM)

Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, SE-171 77, Solna, Sweden.

Jenny Forshed (J)

Cancer Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, SE-171 65, Solna, Sweden.

Karl Kölbeck (K)

Lung Oncology Center, Cancer Theme, Karolinska University Hospital, SE-171 76, Solna, Sweden.

Maria Olin (M)

Lung Oncology Center, Cancer Theme, Karolinska University Hospital, SE-171 76, Solna, Sweden.

Roger Henriksson (R)

Department of Radiation Sciences and Oncology, University of Umeå, SE-901 87, Umeå, Sweden.

Janne Lehtiö (J)

Cancer Proteomics Mass Spectrometry, Department of Oncology-Pathology, Karolinska Institutet, Science for Life Laboratory, SE-171 65, Solna, Sweden.

Carol Tishelman (C)

Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, SE-171 77, Solna, Sweden.
Center for Health Economy, Informatics and Health System Research (CHIS), Stockholm Health Care Services (SLSO), Region Stockholm, SE-113 65, Stockholm, Sweden.
The Centre for Rural Medicine (Glesbygdsmedicinskt Centrum GMC), Region Västerbotten, SE-923 31, Storuman, Sweden.

Lars E Eriksson (LE)

Division of Innovative Care Research, Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, SE-171 77, Solna, Sweden. lars.eriksson@ki.se.
School of Health Sciences, City, University of London, Northampton Square, London, EC1V 0HB, United Kingdom. lars.eriksson@ki.se.
Department of Infectious Diseases, Karolinska University Hospital, SE-141 86, Huddinge, Sweden. lars.eriksson@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH